Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Date:9/22/2009

deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 22, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through lice
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
2. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
3. ER Doctor Demonstrates Breast Pump on Live TV with Patented New Freemie Hands-Free System
4. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
5. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
6. Abbott HIV Test Demonstrates Earlier Disease Detection
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
8. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
9. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
10. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
11. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, ... (FPWR), a nonprofit organization dedicated to supporting research ... syndrome (PWS), announced today that FPWR has received ... Irina Shaulov contributed $1 million in ... initiatives.  "Our ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... poster presentation at the International Society for Cellular ... chronic Achilles tendinosis currently in a Phase 1/2 ... 29 th from 5:30 PM to 7:00 ...
(Date:5/20/2015)... May 20, 2015 This year has ... for lawns. US Patented Pearl’s Premium Ultra Low ... around the country that are coming out of record ... a number of major global concerns related to water, ... grass – the alternative to the standard, water-wasting, chemical-treated ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... 9 A homegrown New Jersey company is,earning ... of pharmaceuticals everywhere. Secure Symbology, (http://www.securesymbology.com ), a ... an,Honored Finalist as Emerging Business of the Year ... its vision to wipe out counterfeit drugs,worldwide. ...
... Extension Provides Members of University HealthSystem Consortium With Broad ... ... 9 Baxter International,Inc. (NYSE: BAX ) announced today ... signed a new two-year,contract extension on behalf of UHC valued ...
... Cell Therapeutics, Inc. (CTI),(Nasdaq: CTIC ; MTAX) management will present at ... pm at,the Palace Hotel in San Francisco. The conference will also ... webcast can be accessed at, http://www.cticseattle.com . ... BIO CEO & Investor Conference ...
Cached Biology Technology:Secure Symbology: Making New Jersey Proud While Saving Lives 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 2Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products 3
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Pauling Institute at Oregon State University have discovered yet another ... vegetables is so good for you it provides not ... complex mechanism of epigenetics. Epigenetics, an increasing focus of ... code, but also to the way that diet, toxins and ...
... cognitive development is not generally impacted by how much ... to a study from Nationwide Children,s Hospital. This ... the widest range of confounding factors when directly examining ... Insufficient or excessive weight gain in pregnancy ...
... cancer in Northern Ireland, the number of people surviving the ... Each year there are between 50-60 men and ... would have died. The survival rates in Northern Ireland ... in the UK, and its patients are benefiting from improved ...
Cached Biology News:Another mechanism discovered by which sulforaphane prevents cancer 2Gestational weight gain generally does not influence child cognitive development 2More people surviving cancer in Northern Ireland 2
... These handy dispensers save ... glasses, wipers, hats, and other ... benchtop storage bins for small ... and manufacturing. Clear acrylic. Open-slot ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Soil Nematode microRNA ...
... critical to the maintenance of appropriate ... as important and diverse as those ... and stress response, antigen presentation, modulation ... channels, cell cycle regulation, transcription, and ...
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
Biology Products: